Back to Authors

Sabagh, Tarek

A5017509205 | I1330342723

Mayo Clinic

Citations 3

Sorafenib for Advanced and Refractory Desmoid Tumors

New England Journal of Medicine | December 19, 2018 | Volume: 379 | Issue: 25 | Pages: 2417-2428

10.1056/nejmoa1805052 | PMID 30575484

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11500-11500

10.1200/jco.2018.36.15_suppl.11500

N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 644-644

10.1200/jco.2005.23.16_suppl.644